We've updated our Privacy Policy to make it clearer how we use your personal data. We use cookies to provide you with a better experience. You can read our Cookie Policy here.

Advertisement
An image displaying a Newsletter on tablet, laptop & mobile

To continue reading this article, sign up for FREE to

Technology Networks logo


Membership is FREE and provides you with instant access to email newsletters, digital publications, our full content catalogue & more...

Invitrogen Launches new Microarray System to Simplify Immunogenetic Testing

Read time: Less than a minute
Invitrogen has announced the commercial availability of an automated, research-use microarray system designed to simplify immunogenetic testing, including human leukocyte antigen (HLA) research.

The new Prodigy™ system is an advanced DNA and protein analysis tool that can accelerate histocompatibility research, vaccine and drug development, and disease association studies.

The Prodigy system is the first high-throughput, next-generation, sequence-specific oligonucleotide probe system that streamlines sample workflow for hybridizing, detecting and analyzing HLA markers in large-volume variation analysis and genotyping research studies.

The Prodigy system represents a significant advancement in technologies for this type of research, providing scientists with a simplified workflow for cleaner, consistent and reproducible results, while reducing hands-on interaction with the system, resulting in decreased variability, errors and the need for repeat testing.

The Prodigy system features several technological advancements over other systems in the market. It has 5-times the density capacity of current bead-based assays and is enabled by push-button, walk-away automation, enabling researchers to spend valuable time reviewing data or preparing more samples. Prodigy is inherently scalable to include multiplexing capability for more than 500 analytes, while providing high resolution and unmatched efficiency and reliability.

With capacity for more than 500 analytes, the Prodigy system is scalable to accommodate new alleles to be identified in the future, enabling it to be incorporated into existing infrastructure.